Here are relevant reports on : prostate-cancer-diagnostics-market
-
Tissue Diagnostics Market by Product (Consumables (Antibodies, Reagents, Tissue, Probes), Instrument (Processing System, Scanner)), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) & Region - Global Forecast to 2028
The global tissue diagnostics market, valued at US$5.2 billion in 2022, stood at US$5.6 billion in 2023 and is projected to advance at a resilient CAGR of 8.4% from 2023 to 2028, culminating in a forecasted valuation of US$8.4 billion by the end of the period. The new research study consists of an industry trend analysis of the market. Market growth is driven by the growing private diagnostic centers globally, and rising geriatric population with subsequent growth in chronic and infectious diseases.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecast to 2026
The global prostate health market growth is primed to transition from USD 31.8 billion in 2021 to USD 48.9 billion by 2026, showcasing a strong CAGR of 9.0%. Growth in this market is primarily driven by the increasing prevalence of benign prostatic hyperplasia, increasing obesity, investments, funds, and grants for research in prostate health, an increase in the prevalence of prostate cancer, a surge in demand for hormone therapy drugs, emerging therapies for prostate cancer, and an increasing incidence of prostatitis.
- Published: December 2021
- Price: $ 4950
- TOC Available:
-
Cancer Supportive Care Drugs Market by Drug Class (G-CSFS, ESAS, Antiemetics, Bisphosphonates, Opioids, Nsaids), Cancer Type (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Other Cancers) - Global Forecast to 2023
Cancer supportive care also known as palliative care is focused on relieving patients from side effects of cancer therapies. In cancer palliative care, supportive drugs are used to lessen the side effects of cancer treatments. In many cases cancer treatments need to be stopped or doses need to lowered due various reasons such as low blood cell counts. In such cases, cancer supportive drugs such as CSFs enable patients to continue with cancer treatments as well as in other cases, it also allows higher doses of cancer therapies. Cancer being one of the leading causes of death worldwide, there has been increasing focus on cancer treatments. Many cancer treatments comes with various side effects such as fatigue, pain, fertility problems, depression, heartburn, sexual problems, bone diseases and other side effects. With such side effects, there is preference to use supportive care drugs during cancer treatments. Such factors are expected to drive the cancer supportive care drugs market. However, there are some side effects associated with cancer supportive care drugs which may hinder the market growth.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Noninvasive Cancer Diagnostics Market by Instruments (Solid Tumor, Blood Cancer, Lung Cancer, Breast Cancer), Technology (Clinical Chemistry, Immunochemistry, Molecular Diagnostics) - Analysis & Global Forecast to 2019
The global non-invasive cancer diagnostic market is expected to show considerable growth during the forecast period. This is attributed to growing cancer cases worldwide, especially breast and lung cancer. In 2013, in the U.S. there were more than 1,660,290 new cases of all type of cancers diagnosed in 2013 (American Cancer Society). Increased healthcare expenditure and increase research and development activities are some of the other factors driving the growth of this market. However factors such as high cost of treatment, and stringent regulatory guidelines are limiting the market growth.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Prostate Cancer Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment and Global Market Forecast)
Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021
The global cancer immunotherapy market size is projected to grow at a CAGR of 14.0%. Market growth can be attributed to the increasing incidence of cancer, rising demand for therapies with minimal adverse effects, increase in adoption of immunotherapy over other treatment options, and enhanced drug development process. However, stringent regulatory policies and the highly consolidated market which may create an obstacle for the entry of small players are the major factors restraining the growth of this market.
- Published: September 2016
- Price: $ 4950
- TOC Available:
-
Cancer Diagnostics Market by Product (Consumables (Antibodies, Probes), Instruments (Pathology Instruments, Imaging Instruments, Biopsy), Technology (IVD Testing), Application (Breast Cancer, Lung Cancer), End User (Hospitals) & Region - Global Forecast to 2026
The global cancer diagnostics market growth is primed to transition from $17.2 billion in 2021 to $26.6 billion by 2026, showcasing a strong CAGR of 11.5%. This growth is driven by the increasing incidence of cancer and the rise in private diagnostic centers. Opportunities are enhanced by government and healthcare provider recommendations for early cancer screening.
- Published: April 2021
- Price: $ 4950
- TOC Available:
-
Fusion Biopsy Market by Route Type (Transrectal, Transperineal), Product (Equipment, Consumables), Application (Prostate Cancer), End User (Hospitals), and Region - Global Forecast to 2029
The global fusion biopsy market, valued at US$0.61 billion in 2023, stood at US$0.65 billion in 2024 and is projected to advance at a resilient CAGR of 7.1% from 2024 to 2029, culminating in a forecasted valuation of US$0.91 billion by the end of the period. Some main drivers for the growth of the fusion biopsy market are the growing prevalence of prostate cancer, since it's among one of the most common serious health concerns for males on a global scale.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035
The global radioligand therapy market, valued at US$2.36 billion in 2024, stood at US$3.15 billion in 2025 and is projected to advance at a resilient CAGR of 13.2% from 2025 to 2035, culminating in a forecasted valuation of US$10.91 billion by the end of the period. The growth of this market is primarily attributed to factors such as increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, and the rising adoption of PSMA and SSTR PET imaging for patient selection.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
European NGS Services Market by Technology (SBS, SBL, SMRT, Pyrosequencing), Application (Exome Sequencing, CHIP-Seq), End User (Pharmaceutical Companies, Hospital), Disease [Oncology (Prostate, Lung, & Breast Cancer), Rare Diseases) - Forecast to 2020
The NGS services market in Europe is expected to reach USD 1,152 Million by 2020 from USD 444 Million in 2015, at a CAGR of 21% from 2015 to 2020. Factors such as rising preference of NGS over other platforms; rapid and cost-efficient sequencing; rising prevalence of inherited diseases; application of genomics in drug discovery; growing prevalence of cancer and other malignant diseases; and partnerships among companies, R&D centers, and universities are expected to drive market growth. However, high dependence on grants for R&D, lack of analytics, and stringent reimbursement policies are likely to restrict the growth of this market to a certain extent.
- Published: October 2015
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
